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Summary
  A particular challenge for both laryngologists and oncologists is presented by 
the fact that treatment of patients in advanced stages of cancer disease, in whom 
either combined therapy (surgery and adjuvant radiotherapy) or radiotherapy 
alone have been applied, is associated with highly dissatisfying results. Clinical 
trials exploring the application of chemotherapy combined with simultaneous 
radiotherapy are arousing greater interest. This is because the results of recent-
ly published randomised prospective studies and meta analyses show improved 
loco-regional results of this treatment strategy, which in turn improves overall 
survival. Cytostatic drugs used in conjunction with radiotherapy have many func-
tions but, above all, their purpose is to intensify the effects of irradiation which, 
in such treatment schemes, is the leading method. One of the basic factors lim-
iting the application of such strategies is the problem of how to limit the toxici-
ty from one side, while administering a sufﬁ ciently high dose of cytostatics, and 
to continue without any gaps the course of radiation from the other. A problem 
associated with combined therapy is how to ensure the highest concentration of 
cytostatics is in the malignant tumour. The need to break through both of these 
limiting factors has become the subject of intensive research. One of the possi-
ble solutions to these problems is the simultaneous application of irradiation in 
combination with selective intra-arterial chemotherapy. To date, ﬁ nal results are 
still unavailable from phase III clinical trials which are investigating this treat-
ment method. Presented in this paper are the advantages and disadvantages in 
the treatment strategy called the RADPLAT programme. The RADPLAT pro-
gramme is characterised by great local effects, somewhat lesser regional effects 
and still lesser effects in the treatment of micro-metastases. Research is contin-
uing, in order to ﬁ nd methods for the improvement of treatment results, with a 
view to reducing the risks of distant metastases and/or regional treatment fail-
ures.
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BACKGROUND
Current oncology of the head and neck cancer 
is very often faced with a challenge; how to treat 
advanced tumours. Such tumours may be neigh-
bouring structures important to life (large arter-
ies, cranial nerves) and may be characterised by 
their closely deﬁ ned surgical limitations. Despite 
this, surgery supplemented by postoperative ra-
diotherapy remains the basic form of the treat-
ment of patients in advanced stages of the head 
and neck cancer. However, because of poor efﬁ -
cacy and signiﬁ cant increases in side effects, re-
search in this area has intensiﬁ ed worldwide in 
order to ﬁ nd more efﬁ cient methods of treatment 
[1,2]. Presently, one of the area of research which 
are arousing hope is combination radiotherapy 
and chemotherapy, and the greatest interest is 
concerning the concurrent application of radi-
otherapy and chemotherapy. Recently published 
results from prospective randomised trials and 
meta-analyses show that the greatest effects are in 
local treatments and in improvements to surviv-
al among patients treated by combined therapy 
(combined radio-chemotherapy), relative to ra-
diotherapy alone [3,4]. Above all, the combined 
radio-chemotherapy strategy is aimed at intensify-
ing the local effects of radiotherapy and, to a less-
er degree, at reducing the number of cancer cells 
remaining beyond the irradiated volume (distant 
metastases). This results from the fact that in tu-
mours of very advanced stages, destruction of the 
primary tumour and metastases to the lymphat-
ic tissues of the neck is a basic condition for ob-
taining a cure. However, later during follow-up 
the problems of distant metastases and further 
second primary tumours may arise.
One of the basic factors limiting the use of com-
bined radio and chemotherapy is the high level 
of toxicity associated with this treatment strate-
gy. Such treatment may lead to limiting the dose 
of cytostatic drugs, or on the other hand may re-
quire that the radiation course to be prolonged 
[5,6]. One of the most important factors inﬂ u-
encing the results of cytostatic treatment is attain-
ment of the optimal concentration of the drug 
in the target cells. It is commonly assumed that 
the higher concentrations of the drug within the 
tumour cells, the greater the cytotoxic effect will 
be. One method of treatment which attempts to 
meet these expectations is the concurrent appli-
cation of radiotherapy with selective high-dose of 
intra-arterial chemotherapy. Despite a four dec-
ade history of intra-arterial chemotherapy in the 
treatment of head and neck cancer, it is only with 
recent improvements to angiographic techniques 
that are relatively safe intra-arterial application of 
the drug to the immediate surroundings of the 
malignant tumour has become possible.
The RADPLAT programme combines high dose 
intra-arterial cisplatin application into the sur-
roundings of the tumour with concurrent radi-
otherapy. It should be noted that the cisplatin 
doses given in the RADPLAT programme are 
much higher than those used in intra-venous de-
livery. In order to obtain a high concentration of 
cytostatics in the tumour, the drug is delivered 
directly via a catheter inserted into the arteries 
supplies the drug into the tumour using angiog-
raphy. For the purposes of limiting the systemic 
effects of cytostatic drugs on healthy cells, while 
the cisplatin is being delivered arterially, thiosul-
phates are given intravenously, as they act as neu-
tralisers of the cisplatin.
The RADPLAT programme represents an alter-
native to the commonly applied method of ve-
nous delivery of cytostatic drugs in the treatment 
of head and neck cancer. The ﬁ rst attempts at ap-
plying the treatment mentioned above showed 
that there existed the possibility of therapy to pa-
tients whose reached an inoperable stage [7–10]. 
The basic cytostatic drug used in combination 
with radiation is cisplatin. The key to obtaining 
maximum therapeutic effect is to deliver a high 
dose of drug to tumour cells [11]. Some factors 
limit the possibilities of increasing the dose of cis-
platin and it is ﬁ rst necessary to determine the 
degree of toxicity to the renal and myeloid sys-
tems. Intravenous doses greater than 50mg/m2 
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may be toxic to the renal, though use of lower 
doses is associated with poor therapeutic effect 
[12]. Careful control of hydration allows us to in-
crease the dose of cisplatin to 125mg/m2 which 
results in improved treatment effects, though 
further increases in dose are limited by the on-
set of side effects.
The results of clinical trials in the treatment of 
head and neck cancer patients show that the high-
est percentage of response is obtained when cis-
platin and radiation are applied simultaneously. 
At the same time, a clear relationship between 
therapeutic effects and the applied dose of cis-
platin has been shown. Because of this, in 1996, 
Robbins and colleagues proposed treatment by 
the RADPLAT method, which combines intra-
arterial chemotherapy with simultaneous radi-
otherapy for the treatment of patients with ad-
vanced cancers of the head and neck. It should 
be noted, however, that localisation of the tu-
mour within the head and neck region is an ex-
clusive requirement when planning treatment 
by this strategy.
A GENERAL OUTLINE OF TREATMENT ACCORDING TO THE 
RADPLAT PROGRAMME
Radiotherapy
The above radiotherapy programme is realised 
in a conventional strategy of fractionation (1.8–
2.0Gy/day) up to a total dose of around 70Gy to 
the tumour and lymph nodes metastases. In clin-
ical practice, modern radiotherapy techniques 
(IMRT) may allow for an improvement in the 
sparing of healthy tissue, which could be unusu-
ally important because of the need to reduce the 
side effects associated with simultaneous radio-
chemotherapy. It must be underlined that toxic-
ity in healthy tissues is often a limiting factor in 
obtaining a response to treatment [13,14].
Angiography
Angiography is performed according to 
Seldinger’s method, via the arteries below the 
inguinal ligament. A metal guide measuring be-
tween 0.25 and 0.35 is inserted into the artery 
via a Seldinger needle. Using the guide, a cathe-
ter with a haemostatic valve is introduced to the 
femoral artery. Through the existing catheter, 
another is inserted for the selective catheterisa-
tion of branches of the aortic arch. For the pur-
pose of identifying pathological vascularisation, 
selective angiography of the internal and exter-
nal carotid arteries is performed. Angiography 
is carried out with the help of automated syring-
es loaded with non-ionic contrast medium (most 
frequently Omnipaq 300, Nycomed) and a solu-
tion of physiological saline in 50:50 proportions. 
The contrast medium is delivered selectively in 
volumes of 8 to 10ml at a rate of 4–6ml/s. After 
completion of the investigation and removal of 
the catheters, local pressure is applied to the area 
of the femoral arteries for 2 to 6 hours using a 
special pressure dressing. The patient remains 
lying down for the following 24 hours.
Chemotherapy
Cisplatin is given within 1 hour of completing 
irradiation. For tumours which do not cross the 
midline of the body a single inlet to one carot-
id artery is recommended, while in the case of 
tumours which cross the midline, inlets in both 
carotid arteries are used. Cisplatin is given arte-
rially at a dose of 150mg/m2 over 3 to 5 minutes 
with simultaneous intravenous delivery of sodi-
um thiosulphate at a dose of 9g/m2. All patients 
receive 4 courses of cisplatin during irradiation 
on days 1, 8, 15 and 22 or on days 2, 9, 16 and 
23 of radiotherapy.
Chemotherapy details:
1. Dexamethazone 4 mg (iv) the evening prior to 
treatment.
2. Hydration prior to therapy: 1 litre 5% dextrose 
+20mEq KCL+ 2g MgSo4 for 2 hours before de-
livery of cisplatin.
3. Cisplatin at a concentration of 1mg/ml given by 
automated arterial pump at a rate of 1–2ml/sec-
ond.
4. Sodium thiosulphate (9g/m2 in 200 ml distilled 
water, given intravenously during a period of 
15–20 minutes, simultaneously with cisplatin, 
and followed by a dose of 12g/m2 continued for 
the following 6 hours (12g w 1 litre of distilled 
water and infused at a rate of 167ml/min).
5. Hydration after therapy: after receiving thio-
sulphates the patient is given 1 litre of 5% dex-
trose +20mEq KCL.
6. Antiemetic drugs are given in accordance with 
the decision of the physician in charge, and lo-
cal practices.
Dose modiﬁ cation is carried out in the case of:
• granulocyte count (PMN) >1.5×109/l,
• platelet count >75×109/l,
• renal creatinine clearance >50ml/min,
• symptoms of stage II neurotoxicity,
• hearing loss greater than 20dB.
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AN OVERVIEW OF IMPORTANT EXPERIENCES IN THE 
APPLICATION OF THE RADPLAT PROGRAMME
The University of Tennessee, Memphis, USA
Robbins and colleagues [11] published the re-
sults of a phase I clinical trial (toxicity assess-
ment) which assessed the arterial application 
of cisplatin in patients with cancers of the head 
and neck. The maximum tolerable dose (MTD) 
which could be delivered arterially, according to 
those authors, amounted to 150mg/m2/week ap-
plied 4 times at weekly intervals. The authors not-
ed the signiﬁ cant number of cases with complete 
or partial response (86%) and, in group of pa-
tients being treated for relapse, this rate is 63%. 
The results of in vitro studies show a dependency 
between the concentration of the cisplatin and 
the strength of the cytotoxic effect on malignant 
cells which, among other factors, gave us the pos-
sibility to explore the idea of high dose chemo-
therapy in clinical practice.
Further evaluation encompassed 213 patients who 
were enrolled into a phase II of study. In ¹⁄³ of these 
patients it had not been possible to perform initial 
surgical treatment due to signiﬁ cantly advanced 
disease process (28.6% – clinical stage III, 71.4% 
– clinical stage IV) while treatment according to 
the RADPLAT program allowed the attainment of 
complete regression in 91% of cases of primary tu-
mours and in 61% of patients with metastatic dis-
ease to the neck. In the cases of 17 patients a par-
tial regression was observed, 12 required salvage 
therapy, and in only 3 the treatment was of a radical 
intent. General toxicity of the treatment was fairly 
high, speciﬁ cally toxicity grade III or IV mucositis 
which was observed in 56 patients. Haematological 
toxicities of the same degree were seen in 17 pa-
tients, neurological complications were observed 
in 9, and cardiological complications were noted 
in 8 patients. Actuarial 5-years overall survival for 
the whole group was 38.8%.
Additional analyses in the year 2001 showed that 
the patients most at risk of distant metastases are 
those with tumours localised in hypopharynx and 
those with massive local metastases to the neck 
lymph nodes. After follow-up the patients for many 
years the authors concluded that patients treated 
according to the RADPLAT programme:
•  had a poorer prognosis if the tumour was lo-
cated in the lower part of pharynx,
•  had a signiﬁ cantly worsened prognosis in the 
event of massive metastasis to the neck lymph 
nodes,
•  require closely cooperation by a multidiscipli-
nary group with special attention being paid to 
the likely need for salvage therapy to be quick-
ly applied in a signiﬁ cant proportion of pa-
tients.
The RADPLAT programme was also tested on 
small groups of patients with advanced tumours 
of the base of the skull, tumours of the neck in 
the N3 stage, and tumours of the nasal sinuses. 
A general summary of the results of treatment 
shows the programme has encouraging results in 
these localisations. It is also worth noting that the 
RADPLAT program is highly effective in patients 
with inﬁ ltration of the bones (T4). Complete re-
sponses in the cases amount to 66.7%, and show 
an actuarial 2 year overall survival of 46.3%; (95% 
CI: 30.3–62.3%) [15].
One of the most important purposes of current 
studies under the RADPLAT program is to iden-
tify predictive factors for this form of therapy, for 
the purposes of deﬁ ning patient qualiﬁ cation cri-
teria for this type of treatment. In an analysis un-
dertaken by van der Broek and co-workers, fac-
tors such as the volume of the primary tumour, 
the volume of lymph node metastases, total vol-
ume of the tumour plus lymph nodes, localisa-
tion of metastases in the lower levels of the neck, 
low Hb level, large losses in body mass prior to 
treatment, and unilateral arterial cisplatin ther-
apy were studied, though only the volume of the 
primary tumour and unilateral application of cis-
platin showed a negative effect on patient surviv-
al [16]. Similarly, Doweck et al. [17] conﬁ rmed 
that the volume of the tumour is the strongest 
prognostic factor among patients treated accord-
ing to the RADPLAT programme.
Another particularly important area of study is 
the assessment of quality of life for patients after 
completion of therapy. What is obvious is that ef-
ﬁ ciency of the RADPLAT programme is compara-
ble with simultaneous intravenous chemotherapy 
and radiotherapy programms, and comparison 
leads to a very signiﬁ cant ﬁ nding. To date, stud-
ies comparing the two methods of treatment have 
shown no difference in the quality of life of pa-
tients who have completed the therapy [18].
In any case, in squamous cell carcinomas of the 
head and neck, distant metastases do not rep-
resent a general negative indicator for poor re-
sponse to treatment, it is in advanced stages of 
disease, and particularly in the case of massive me-
tastasis to the cervical lymph nodes that remote 
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metastases begin to take on signiﬁ cance. Also 
associated with this is the use of highly selective 
therapy, such as introducing drugs to speciﬁ c ar-
teries so that the maximum possible dose will be 
delivered to the tumour while a minimum will 
be delivered to the surroundings (healthy tis-
sue) leading one to question the effects of such 
treatment strategies on the frequency of system-
ic failure. According to Doweck and colleagues 
[19], who observed these patients, treated using 
the RADPLAT method, those at the greatest risk 
for non-responsiveness to the system are cases 
with metastases to many levels of the neck and 
those with tumours localised in the hypopharynx. 
Among patients with clinical parameters other 
than those described above, results of treatment 
by the RADPLAT programme are likely to show 
less effectiveness.
REGRESSION OF TUMOURS OF THE NECK AND 
RADPLAT: THE ROLE OF SURGERY
Close cooperation with head and neck surgeons 
is of vital importance. This is because of the fact 
that, in patients who fail to attain complete re-
gression of the lesion in the cervical lymph nodes, 
it will be necessary to undertake surgical salvage 
treatment at the completion of radiotherapy. This 
is important because a lack of control in inacces-
sible regions remains a key factor for lack of re-
sponse to therapy among patients who have un-
dergone treatment according to the RADPLAT 
programme. Surgical salvage therefore represents 
a key element in the treatment protocol. This un-
derlines the need for interdisciplinary surgeons, 
who are involved in qualiﬁ cation of patients for 
the programme, support during radio-chemo-
therapy course, and during the follow-up, which 
is when salvage surgery may be required.
The Netherlands Cancer Institute, Amsterdam, 
Holland
In 1997 this Dutch centre adapted the RADPLAT 
programme for use in a phase II clinical trial, ac-
cording to an identical protocol to that proposed 
by Robbins and colleagues. The Dutch research-
ers offered this form of treatment to patients for 
whom surgical operations were impossible ow-
ing to advanced stage of the primary tumour or 
the presence of massive metastasis to the lymph 
nodes. Out of 73 patients who qualiﬁ ed for anal-
ysis, 88% showed complete remission. Two year 
disease free survival and 2 year overall survival 
without symptoms of disease was noted in 65% 
and 45% respectively. The authors observed that 
though the treatment was typically well tolerat-
ed, the procedure was associated with 1 death 
and that 17% of patients showed grade IV hae-
matological toxicity symptoms. Aside from hae-
matological symptoms, no other grade IV toxic-
ity was observed [22]. Encouraged by the good 
results of treatment with good tolerance for the 
programme, the authors decided to carry out a 
full evaluation in the phase III randomised clini-
cal trial (RADPLAT vs. intravenous cisplatin + si-
multaneous radiotherapy). This study is current-
ly in the enrolment phase in 4 Dutch centres. At 
this point it should be pointed out that our cen-
tre in Poznan has also accepted the invitation of 
the Dutch researchers to take part in the trial.
The George Washington University, 
Washington, USA
A study using a RADPLAT programme was be-
gun in this centre in 1994 under the leadership of 
Wilson. However, the treatment scheme differed 
from that proposed in Memphis and Amsterdam. 
The existing programme was modiﬁ ed in the fol-
lowing manner: the treatment was carried out in 
a sequential manner, wherein the ﬁ rst phase was 
the application of arterially cisplatin at a dose of 
150mg/m2/week for four weeks (neoadjuvant 
chemotherapy) after which radiation treatment 
was begun. On the basis of observations of a group 
of 58 patients, Wilson and colleagues [21] came 
to the conclusion that their treatment scheme 
(arterial neoadjuvant chemotherapy and radio-
therapy) allowed a larger proportion of patients 
to maintain systemic function while simultaneous-
ly maintaining good tolerance to the treatment. 
From the practical point of view, it should be not-
ed that the total treatment time from the ﬁ rst day 
of chemotherapy to completion of the course of 
radiotherapy is signiﬁ cantly longer than that of 
the classic RADPLAT programme. Besides that, 
the size of the study group did not allow for the 
extraction of results which may provide strong 
evidence. It should be noted that one of the un-
derlying ideas of the programme is the intensiﬁ -
cation of therapy (dose/time) which, being mod-
iﬁ ed in the programme as proposed by Wilson, 
has an effect on subsequent plans.
Modiﬁ cations to the RADPLAT Programme
Pento-RADPLAT
Intensive treatment, such as that proposed in 
the RADPLAT programme, causes a signiﬁ cant 
number of patients to develop skin ﬁ brosis. That 
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being the case, among patients treated with ir-
radiation and chemotherapy (in stages of ad-
vancement N2-N3), surgical procedures are car-
ried out to remove the „remaining” metastatic 
nodes. For the purposes of limiting of the inten-
sity of these ﬁ brosis symptoms, authors have pro-
posed to introduce pentoxyphyllin from the ﬁ rst 
day of radiation treatment in doses of 400mg giv-
en four times daily. This treatment was contin-
ued during follow-up several following months. 
A comparative analysis of two groups of patients 
was undertaken. The results showed that the pa-
tients given the prophylactic drug develop ﬁ -
brosis (stage 0–II) in 60% of cases, while those 
who did not receive treatment developed ﬁ bro-
sis in 80% of cases. Similarly, the scale of grade 
III and IV complications was reduced among pa-
tients treated with pentoxyphyllin: 20% among 
those taking the drug vs. 40% among those who 
did not receive the treatment. It should be not-
ed that these initial results, with regards to the 
use of pentoxyphyllin, indicated that it may be 
possible to make use of such procedures and fur-
ther study is required.
Neo-RADPLAT
The treatment of patients with advance tumours 
(T2 and T3) localised in the oral cavity and in 
the mid-portion of the throat remains problem-
atic in that, to date, initial surgery is still associ-
ated with a signiﬁ cant reduction in the quality of 
life. This problem resulted in the concept of pre-
operative radiotherapy using doses up to 50Gy 
with simultaneous intra-arterial cisplatin chemo-
therapy (Neo-RADPLAT). After this initial treat-
ment, patients in whom a complete remission 
cannot be obtained may be offered a “conserv-
ative” RADPLAT programme which frequently 
takes the form of removal of the tumour. What 
is worth noting here is the fact that complete re-
mission after simultaneous radio-chemotherapy 
may be observed in as many as 75% of all patients 
treated [10]. That being the case, it seems very 
important to continue testing this type of modi-
ﬁ cation to the RADPLAT programme.
Multi-RADPLAT
Treatment according to the RADPLAT pro-
gramme requires a high level of organisation and 
qualiﬁ ed personnel, which is why, in Poland, after 
completing the phase III study mentioned earli-
er, there is likely to be a delay in dissemination of 
the technique as a routine means of treatment. 
Eden In countries such as the United States, 
routine treatment according to the RADPLAT 
programme may cause organisational problems. 
This being the case, it may be that provision of 
this form of therapy in typical oncology centres 
may be impossible. Because of such problems, 
and In order to determine the potential for in-
troducing the RADPLAT programme to routine 
therapies in clinical practice, a study was proposed 
which would include 11 selected American cen-
tres (3 with experience with RADPLAT and 8 
with no experience). This study was realized in 
the form of the clinical trial RTOG 9615 which 
was carried out between 1997 and December 
1999. Sixty-seven patients were enrolled: all pa-
tients were in stage IV and were located in the 
oral cavity, the oropharynx or larynx. In the in-
itial ﬁ ndings of RTOG 9615, it was noted that 3 
or 4 courses of cisplatin could be administered 
without harm in 84% of the cases. Among the pa-
tients studied, early toxicity from treatment was 
as follows: stage III=45%, stage IV=35% and stage 
V=3%. The greatest problem was the occurrence 
of mucositis of grades III and IV. Such problems 
were noted in 47% and 10% of patients, respec-
tively. Centres with experience in treatment ac-
cording to the programme recorded grade IV 
toxicity in 14% of patients while centres with no 
previous experience observed such toxicity in 
47%. Two year disease free survival among the 
whole group amounted to 46% and total surviv-
al to 63% [9]. The conclusion of the study was 
that treatment according to the RADPLAT pro-
gramme is possible in typical oncology centres 
in the United States.
INTENSIFICATION OF RADIOTHERAPY WITHIN THE 
RADPLAT PROGRAMME
In cases of advanced cancers of the head and 
neck, intensiﬁ cation of radiotherapy is a recog-
nised means of improving the results of treat-
ment. On this basis, Foote and colleagues [22] 
undertook to attempt such a boost within the lim-
its of RADPLAT by increasing the rate of irradi-
ation by means of concomitant boost. Initial ob-
servations of a group of 19 patients showed that 
such treatment was unacceptable owing to com-
plications. Among others, the authors reported 
2 deaths resulting from sepsis after chemother-
apy and 1 case in which amputation of the lower 
extremities became necessary, owing to throm-
bosis. The number of chemotherapy cycles was 
therefore reduced from 4 to 3 for the remain-
der of the study, though toxicity was not accept-
able. From this, it may be deduced that the orig-
inal RADPLAT programme represents optimal 
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levels of tolerance and side effects and attempts 
to further intensify the therapy produce no fur-
ther therapeutic beneﬁ ts.
CONCLUSIONS
To date, the ﬁ nal results of the randomised 
phase III clinical trials for the assessment of the 
RADPLAT programme are unknown. Groups 
which have initially veriﬁ ed the method include 
Robbins and colleagues [8] of the oncology cen-
tre in Memphis and Balma and co-workers in the 
National Cancer Institute (NKI) of Holland in 
Amsterdam [20].
The RADPLAT programme represents a particu-
larly interesting proposition for the treatment of 
advanced cancers of the head and neck in which 
conventional methods of treatment (surgery and 
radiotherapy) give highly unsatisfactory results 
of treatment or simply cannot be applied. The 
programme is associated with increased logisti-
cal problems and signiﬁ cant toxicity, but when 
viewed in context with the very promising re-
sults of treatment, these difﬁ culties are accepta-
ble. However, until the phase III clinical trials are 
complete there will be a lack of evidence to sup-
port this treatment in routine practice.
Our centre in Poznań has completed an initial 
analysis of results from a pilot study which show 
complete agreement with the observations of the 
American and Dutch researchers.
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